Literature DB >> 31209397

Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study.

Cristina Navarro-Soriano1, Miguel-Angel Martínez-García2, Gerard Torres3, Ferrán Barbé4,5, Candela Caballero-Eraso5,6, Patricia Lloberes7, Trinidad Diaz Cambriles8, María Somoza9, Juan F Masa10, Mónica González11, Eva Mañas12, Mónica de la Peña13, Francisco García-Río5,14, Josep María Montserrat5,15, Alfonso Muriel16, Grace Oscullo1, Laura Feced Olmos1, Alberto García-Ortega1, David Calhoun17, Francisco Campos-Rodriguez5,18.   

Abstract

Refractory hypertension (RfH) is defined as a lack of blood pressure control despite the administration of at least 5 anti-hypertensive drugs. The factors associated with its natural history are unknown. This study aimed to evaluate both the incidence of RfH in an cohort of patients with resistant hypertension (RH) and the factors involved in that progression. This was an observational prospective multicenter study (24 centers) with 172 patients with confirmed RH (24-h ABPM) who underwent a further 24 h ABPM study at the end of the follow-up. Prospective information was obtained from all patients in their corresponding Hypertension Units via a standard clinical protocol, and they all underwent a sleep study. Thirty patients were diagnosed with RfH (17.4%) after a mean follow-up of 57 months, despite the prescription of a greater number of long-acting thiazide-like diuretics and mineralocorticoid receptor antagonists. The factors associated with progression to RfH were: a longer period since the diagnosis of RH (OR: 1.06, 95% CI: 1.01-1.1, p = 0.007); the HbA1c concentration (OR: 1.42, 95% CI: 1.42-1.8; p = 0.005); the initial heart rate (OR: 1.05, 95% CI: 1.01-1.09, p = 0.004); and poor adherence to continuous positive airway pressure (CPAP) in cases of obstructive sleep apnea (OR: 3.36, 95% CI: 1.47-7.7, p = 0.004). In conclusion, a considerable percentage of patients evolved from the RH to the RfH phenotype despite changes in their treatment. Some easily measurable variables, such as heart rate, the time since the diagnosis, the HbA1c level, and the presence of untreated obstructive sleep apnea (or poor adherence to CPAP) have been demonstrated to be prognostic factors in the progression to RfH.

Entities:  

Keywords:  Clinical phenotype; Continuous positive airway pressure; Refractory hypertension; Resistant hypertension

Mesh:

Year:  2019        PMID: 31209397     DOI: 10.1038/s41440-019-0285-8

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  24 in total

1.  Long-term risk of sustained hypertension in white-coat or masked hypertension.

Authors:  Giuseppe Mancia; Michele Bombelli; Rita Facchetti; Fabiana Madotto; Fosca Quarti-Trevano; Hernan Polo Friz; Guido Grassi; Roberto Sega
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

2.  Risk of hypertension among different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies.

Authors:  Atieh Mirzababaei; Hadis Mozaffari; Sakineh Shab-Bidar; Alireza Milajerdi; Kurosh Djafarian
Journal:  J Hum Hypertens       Date:  2018-12-19       Impact factor: 3.012

Review 3.  Hypertension in Blacks: Individualized Therapy Based on Renin/Aldosterone Phenotyping.

Authors:  J David Spence; Brian L Rayner
Journal:  Hypertension       Date:  2018-06-25       Impact factor: 10.190

4.  Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors:  MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

5.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.

Authors:  Dharam J Kumbhani; P Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Kevin Crowley; Shinya Goto; E Magnus Ohman; George L Bakris; Todd S Perlstein; Scott Kinlay; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2012-11-09       Impact factor: 29.983

Review 6.  What does endotyping mean for treatment in chronic obstructive pulmonary disease?

Authors:  Alvar Agustí; Bartolome Celli; Rosa Faner
Journal:  Lancet       Date:  2017-09-02       Impact factor: 79.321

7.  Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.

Authors:  Sante D Pierdomenico; Domenico Lapenna; Anna Bucci; Roberta Di Tommaso; Rocco Di Mascio; Bianca M Manente; Maria P Caldarella; Matteo Neri; Franco Cuccurullo; Andrea Mezzetti
Journal:  Am J Hypertens       Date:  2005-11       Impact factor: 2.689

8.  Microcirculation and biomarkers in patients with resistant or mild-to-moderate hypertension: a cross-sectional study.

Authors:  Camillo L C Junqueira; Maria Eliane C Magalhães; Andréa Araújo Brandão; Esmeralci Ferreira; Fátima Z G A Cyrino; Priscila A Maranhão; Maria das Graças C Souza; Daniel Alexandre Bottino; Eliete Bouskela
Journal:  Hypertens Res       Date:  2018-04-23       Impact factor: 3.872

9.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.

Authors:  Krishna K Gaddam; Mari K Nishizaka; Monique N Pratt-Ubunama; Eduardo Pimenta; Inmaculada Aban; Suzanne Oparil; David A Calhoun
Journal:  Arch Intern Med       Date:  2008-06-09

10.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

View more
  5 in total

1.  Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study.

Authors:  Mohammed Siddiqui; Hemal Bhatt; Eric K Judd; Suzanne Oparil; David A Calhoun
Journal:  Am J Hypertens       Date:  2020-08-04       Impact factor: 2.689

2.  Reserpine: A New Consideration of and Old Drug for Refractory Hypertension.

Authors:  Matthew R Weir
Journal:  Am J Hypertens       Date:  2020-08-04       Impact factor: 3.080

Review 3.  Resistant/Refractory Hypertension and Sleep Apnoea: Current Knowledge and Future Challenges.

Authors:  Grace Oscullo; Gerard Torres; Francisco Campos-Rodriguez; Tomás Posadas; Angela Reina-González; Esther Sapiña-Beltrán; Ferrán Barbé; Miguel Angel Martinez-Garcia
Journal:  J Clin Med       Date:  2019-11-05       Impact factor: 4.241

Review 4.  Characteristics of hypertension in obstructive sleep apnea: An Asian experience.

Authors:  Satoshi Hoshide; Kazuomi Kario; Yook-Chin Chia; Saulat Siddique; Peera Buranakitjaroen; Kelvin Tsoi; Jam Chin Tay; Yuda Turana; Chen-Huan Chen; Hao-Min Cheng; Van Minh Huynh; Sungha Park; Arieska Ann Soenarta; Guru Prasad Sogunuru; Tzung-Dau Wang; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-03-11       Impact factor: 3.738

5.  Refractory Hypertension and Risks of Adverse Cardiovascular Events and Mortality in Patients With Resistant Hypertension: A Prospective Cohort Study.

Authors:  Claudia R L Cardoso; Gil F Salles
Journal:  J Am Heart Assoc       Date:  2020-08-27       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.